Latest Proprietary Technology News

Plenti Group Limited reported a robust FY25 with a 126% jump in Cash NPAT to $13.8 million and a 19% increase in its loan portfolio to $2.5 billion, driven by technology enhancements and strategic partnerships.

Plenti Group Limited has reported a remarkable turnaround with a $24.8 million profit for the year ended March 2025, reversing a loss from the previous year. The fintech lender also announced its upcoming Annual General Meeting and director nomination deadlines.

Worley Limited has reaffirmed its FY25 financial outlook, targeting low double-digit EBITA growth and margins between 8-8.5%, supported by a robust $9.4 billion bookings pipeline and a strategic operational reorganisation.

Australian Bond Exchange Holdings has completed a $683,180 private placement, issuing over 17 million shares to strengthen its financial position and support expansion and cost-cutting initiatives.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Australian Bond Exchange Holdings (ASX: ABE) announces the resignation of director Anthony Hartman and the appointment of Robert Shaw and Mark O’Leary to its board, signaling a strategic boost in expertise.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.

Computershare Limited reaffirmed its FY25 guidance at the Macquarie Australia Conference, projecting a 15% increase in management EPS supported by strong revenue growth and disciplined capital management.

Vection Technologies has landed a $1.2 million grant to lead an innovative XR and AI digital twin project aimed at transforming real-time product intelligence in food and beverage manufacturing.

Nanollose Limited has achieved a significant milestone by blending its Nullarbor-20™ sustainable fibre with Australian merino wool to produce pilot blankets, while also completing a $672,000 placement to fund ongoing commercialisation efforts.

Vectus Biosystems advances its lead fibrosis drug VB0004 with validated Phase I safety data and strategic cost reductions, while actively pursuing licensing partnerships in China.

NoviqTech has advanced its blockchain-based sustainability solutions, pioneering real-world asset tokenisation and expanding its investor base through OTCQB trading in the US.